Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-HSCT for Stage 4/M Neuroblastoma
NCT05303727Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in neuroblastoma, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Overall Survival at 3 years and Event-Free Survival at 3 years. Planned start Aug 2022; status: not yet recruiting.
02
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05303727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303727.